Baylor Genetics provides clinical genetic testing and genomic analysis across rare diseases, pediatric genetics, reproductive health, hereditary cancer, and metabolic disorders. Operating as a joint venture between Baylor College of Medicine and HU Group Holdings, the company has performed over 4 million tests worldwide and holds accreditation from CLIA, CAP, and the New York State Department of Health.
The organization offers a comprehensive diagnostic platform spanning whole genome sequencing, whole exome sequencing, RNA sequencing, chromosomal microarray analysis, and specialized genetic assays. Each result is interpreted by a team comprising PhDs, MDs, laboratory directors, and genetic counselors, combining clinical depth with operational scale.
Baylor Genetics has driven innovation in genomic testing for nearly 50 years, from pioneering early chromosomal microarray and whole exome sequencing technologies to current whole genome sequencing and multiomics approaches. The company serves a global client base of healthcare providers and patients requiring precision diagnostics across a range of medical conditions.